Owing to their vast potential in controlling disease-associated gene expression, RNAi therapeutics have emerged as a key segment of the market; several big pharma players have undertaken RNAi focused initiatives.
In addition to effective gene silencing, these candidates can be deployed for applications related to precision medicine. Studies have also demonstrated the safety of RNAi therapeutics for in systemic delivery, paving the way for systemic applications of the therapy. A number of novel and sophisticated technologies / platforms have been / are being developed to overcome the challenges associated with RNAi therapeutics, as well as further enhance their specificity and stability. Further, considering their high knockdown efficiency, high target specificity and extended silencing ability, RNAi has now been established as a powerful tool for gene silencing. It is worth highlighting, RNAi has potential applications in treating several viral infections and tumors in addition to its ability in gene function determination. However, despite the numerous benefits offered by RNAi therapies, developers often face concerns related to the stability and targeted delivery of their candidates. In order to mitigate the aforementioned challenges, several players have developed novel technologies and delivery systems to ensure target specific delivery of these molecules.
To request a sample copy / brochure of this report, please visit
With four approved drugs and several therapy candidates being evaluated in late stages of clinical development, the RNAi therapeutics domain presents a significant opportunity for biopharmaceutical developers. In addition, a number of RNAi therapeutics are being developed to target rare and genetic clinical conditions, such as Alpha 1-Antitrypsin Disease, Alport Syndrome, Amyloidosis and Muscular Dystrophy (Facioscapulohumeral Muscular Dystrophy and Oculopharyngeal Muscular Dystrophy). It is also worth highlighting that over 2,100 patents have been filed / granted, highlighting the continuous pace of ongoing innovation in this field. Given the high research activity and ongoing technology advancements, the RNAi therapeutics market is poised to grow at a steady pace in the foreseen future. An insightful technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
For additional details please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market/278.html or email email@example.com
You may also be interested in the following titles:
- Targeted protein degradation market, 2022-2035
- Cell Therapy Manufacturing Market, 2021-2030
- Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at firstname.lastname@example.org
+1 (415) 800 3415
+44 (122) 391 1091
Facebook - https://www.facebook.com/RootsAnalysis
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis